申报人的研究方向是肿瘤微环境对乳腺癌发生发展的调控机制。主要学术成绩：1.发现巨噬细胞和癌细胞通过炎症因子CCL18和GM-CSF，形成正循环信号通路促进三阴乳腺癌EMT和转移。成果发表在Cancer Cell，为第一作者。2.进一步发现炎症因子通过组蛋白去乙酰化调控microRNA，靶向STAT6和PPAR通路，调控巨噬细胞激活。成果发表在Nat Comm,为共同通讯兼第一作者。3.此外，关于微环境促癌信号通路的其他研究，以共同通讯/第一作者发表在Oncoimmuology等肿瘤免疫学杂志共4篇。4.主持广东省自然杰出青年项目、国家自然面上项目、中山大学青年教师重点培育项目，获得中山大学博济人才、逸仙人才等奖励。此基础上，拟通过术前化疗的临床标本分析和模拟人真实肿瘤微环境的体内外模型，进一步阐明微环境调控乳腺癌免疫抑制和治疗抵抗的炎性信号网络，发展靶向其中节点分子的乳腺癌新型精准治疗策略

My major research interest is the regulation of breast cancer progression and metastasis by tumor microenvironment. Following is a brief introduction of my findings:1) Identification of a positive feedback loop between cancer cells that have undergone epithelial-mesenchymal transition and macrophages, which is essential to breast cancer metastasis (Su S.C., et, al. Cancer Cell, 2014, IF:23.523；Su S.C., et, al. Oncoimmunology 2014, IF:6.266) (first author). 2) Identification of a novel intracellular signaling network which is essential to maintain the macrophage activation. (Su S.C., et, al. Nature Communications 2015, IF=11.470). (first author and co-correspondent author).3) Identification of several other players in tumor microenvironment which promote cancer progression: Nerve fibres in breast cancer indicate tumor progression (Huang D., et,al. Medicine 2014, IF:5.723) (co-first author and co-correspondent author); Long noncoding RNA NBAT1 mediated by inflammatory cytokine regulates breast cancer metastasis by via DKK1 and PRC2 (Hu P.N., et, al. Oncotarget 2015, IF=6.359) (co-correspondent author); CCL18 mediates hepatic cancer metastasis through PITPNM3 (He C.H., et,al. Chinese Science Bulletin 2014) (co-first author).My next move will focus on dissecting the molecular mechanisms by applying human sample-based approaches, which include humanized mice, patient derived tumor xenografts, clinical samples and online clinical databases. I will use high throughput methods such as RNA sequencing and DNA microarray, and in vivo models to define cellular interactions and the novel inflammatory signaling networks involved in immunosuppression and drug resistance. Furthermore, a translation from the basic research finding to clinical practice will be emphasized.